Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis
Allogeneic hematopoietic SCT is an effective treatment in accelerated (AP) or blast phase (BP) CML. Imatinib (IM) has transient but significant activity in advanced phases of CML, which may permit early allografting for responding patients. To identify prognostic factors in allograft recipients prev...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2012-06, Vol.47 (6), p.810-816 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 816 |
|---|---|
| container_issue | 6 |
| container_start_page | 810 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 47 |
| creator | Khoury, H J Kukreja, M Goldman, J M Wang, T Halter, J Arora, M Gupta, V Rizzieri, D A George, B Keating, A Gale, R P Marks, D I McCarthy, P L Woolfrey, A Szer, J Giralt, S A Maziarz, R T Cortes, J Horowitz, M M Lee, S J |
| description | Allogeneic hematopoietic SCT is an effective treatment in accelerated (AP) or blast phase (BP) CML. Imatinib (IM) has transient but significant activity in advanced phases of CML, which may permit early allografting for responding patients. To identify prognostic factors in allograft recipients previously treated with IM, we analyzed 449 allogeneic hematopoietic SCTs performed from 1999 to 2004 in advanced-phase CML, using the data reported to the Center for International Blood and Marrow Transplant Research. CML patients in second chronic phase (CP2,
n
=184), AP (
n
=185) and BP (
n
=80) received HLA-identical sibling (27%), related (3%), or matched or mismatched unrelated donor (70%), peripheral blood (47%) or BM (53%) hematopoietic SCT after myeloablative (78%) or non-myeloablative (22%) conditioning. In all, 52% in CP2, 49% in AP and 46% in BP received IM before hematopoietic SCT. Disease-free survival was 35–40% for CP2, 26–27% for AP and 8–11% for BP. Cumulative incidence of acute and chronic GVHD and TRM were not affected by the stages of CML or pre-hematopoietic SCT IM exposure. Multivariate analyses showed that conventional prognostic indicators remain the strongest determinants of transplant outcomes. In conclusion, there are no new prognostic indicators of the outcomes of allogeneic hematopoietic SCT for advanced-phase CML in the IM era. |
| doi_str_mv | 10.1038/bmt.2011.194 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1020845899</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A293949304</galeid><sourcerecordid>A293949304</sourcerecordid><originalsourceid>FETCH-LOGICAL-c650t-d27dfd45adb6e66d285609cac8e953a6dfd3bec4e811374860a372828a046cfa3</originalsourceid><addsrcrecordid>eNqN0s1rFDEYB-Agit1Wb55lQCwenDXfk3irix-FLYrU85DJZHZTMsk2yRz635txV9tKEZnDQPLkffPxA-AFgksEiXjXjXmJIUJLJOkjsEC04TUjnD0GC4i5qAnh8ggcp3QFIaIUsqfgCCMpOCd8Ady3GDY-pGx1NSidQ0zVEGIVpqzDaFJlfaWcCxvjTSE5Kp92Tvmssg3-F11drGeVt6ayYxn2tqtMVO8rVa3OP1xcfq-UV-4m2fQMPBmUS-b54X8Cfnz6eLn6Uq-_fj5fna1rzRnMdY-bfugpU33HDec9FoxDqZUWRjKieJkkndHUCIRIQwWHijRYYKEg5XpQ5AS82dfdxXA9mZTb0SZtXNm3CVNqEcRQUCak_A-KJJQEN7jQV3_RqzDFcrTUYk4xakQj2L9UqSU4Q6XrrdooZ1rrh1BuVs-t2zMsiaSSQFrU8gFVvt6MVgdvBlvG7y04vbNga5TL2xTcNL9Vug_f7qGOIaVohnYXy-PFm7LJdo5VW2LVzrFqS6wKf3k41NSNpv-Df-eogNcHoJJWbigx0TbdOiYlZGguVO9dKlN-Y-Ld23mg8U-4X9_E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1018651993</pqid></control><display><type>article</type><title>Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis</title><source>MEDLINE</source><source>Nature Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Khoury, H J ; Kukreja, M ; Goldman, J M ; Wang, T ; Halter, J ; Arora, M ; Gupta, V ; Rizzieri, D A ; George, B ; Keating, A ; Gale, R P ; Marks, D I ; McCarthy, P L ; Woolfrey, A ; Szer, J ; Giralt, S A ; Maziarz, R T ; Cortes, J ; Horowitz, M M ; Lee, S J</creator><creatorcontrib>Khoury, H J ; Kukreja, M ; Goldman, J M ; Wang, T ; Halter, J ; Arora, M ; Gupta, V ; Rizzieri, D A ; George, B ; Keating, A ; Gale, R P ; Marks, D I ; McCarthy, P L ; Woolfrey, A ; Szer, J ; Giralt, S A ; Maziarz, R T ; Cortes, J ; Horowitz, M M ; Lee, S J</creatorcontrib><description>Allogeneic hematopoietic SCT is an effective treatment in accelerated (AP) or blast phase (BP) CML. Imatinib (IM) has transient but significant activity in advanced phases of CML, which may permit early allografting for responding patients. To identify prognostic factors in allograft recipients previously treated with IM, we analyzed 449 allogeneic hematopoietic SCTs performed from 1999 to 2004 in advanced-phase CML, using the data reported to the Center for International Blood and Marrow Transplant Research. CML patients in second chronic phase (CP2,
n
=184), AP (
n
=185) and BP (
n
=80) received HLA-identical sibling (27%), related (3%), or matched or mismatched unrelated donor (70%), peripheral blood (47%) or BM (53%) hematopoietic SCT after myeloablative (78%) or non-myeloablative (22%) conditioning. In all, 52% in CP2, 49% in AP and 46% in BP received IM before hematopoietic SCT. Disease-free survival was 35–40% for CP2, 26–27% for AP and 8–11% for BP. Cumulative incidence of acute and chronic GVHD and TRM were not affected by the stages of CML or pre-hematopoietic SCT IM exposure. Multivariate analyses showed that conventional prognostic indicators remain the strongest determinants of transplant outcomes. In conclusion, there are no new prognostic indicators of the outcomes of allogeneic hematopoietic SCT for advanced-phase CML in the IM era.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/bmt.2011.194</identifier><identifier>PMID: 21986636</identifier><identifier>CODEN: BMTRE9</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adolescent ; Adult ; Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Benzamides ; Biological and medical sciences ; Blast ; Blood ; Bone marrow ; Bone marrow transplantation ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Care and treatment ; Cell Biology ; Child ; Chronic myeloid leukemia ; Data processing ; Disease-Free Survival ; Donors ; Female ; Graft-versus-host reaction ; Hematologic and hematopoietic diseases ; Hematology ; Hematopoietic Stem Cell Transplantation ; Hematopoietic stem cells ; Hemopoiesis ; Histocompatibility antigen HLA ; Humans ; Imatinib ; Imatinib Mesylate ; Indicators ; Inhibitor drugs ; Internal Medicine ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical prognosis ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Multivariate analysis ; original-article ; Patient outcomes ; Patients ; Peripheral blood ; Piperazines - administration & dosage ; Protein Kinase Inhibitors - administration & dosage ; Public Health ; Pyrimidines - administration & dosage ; Retrospective Studies ; Siblings ; Stem cell transplantation ; Stem Cells ; Survival ; Survival Rate ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Transplantation ; Transplantation Conditioning ; Transplantation, Homologous ; Transplants & implants</subject><ispartof>Bone marrow transplantation (Basingstoke), 2012-06, Vol.47 (6), p.810-816</ispartof><rights>Macmillan Publishers Limited 2012</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2012 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jun 2012</rights><rights>Macmillan Publishers Limited 2012.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c650t-d27dfd45adb6e66d285609cac8e953a6dfd3bec4e811374860a372828a046cfa3</citedby><cites>FETCH-LOGICAL-c650t-d27dfd45adb6e66d285609cac8e953a6dfd3bec4e811374860a372828a046cfa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/bmt.2011.194$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/bmt.2011.194$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25990514$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21986636$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khoury, H J</creatorcontrib><creatorcontrib>Kukreja, M</creatorcontrib><creatorcontrib>Goldman, J M</creatorcontrib><creatorcontrib>Wang, T</creatorcontrib><creatorcontrib>Halter, J</creatorcontrib><creatorcontrib>Arora, M</creatorcontrib><creatorcontrib>Gupta, V</creatorcontrib><creatorcontrib>Rizzieri, D A</creatorcontrib><creatorcontrib>George, B</creatorcontrib><creatorcontrib>Keating, A</creatorcontrib><creatorcontrib>Gale, R P</creatorcontrib><creatorcontrib>Marks, D I</creatorcontrib><creatorcontrib>McCarthy, P L</creatorcontrib><creatorcontrib>Woolfrey, A</creatorcontrib><creatorcontrib>Szer, J</creatorcontrib><creatorcontrib>Giralt, S A</creatorcontrib><creatorcontrib>Maziarz, R T</creatorcontrib><creatorcontrib>Cortes, J</creatorcontrib><creatorcontrib>Horowitz, M M</creatorcontrib><creatorcontrib>Lee, S J</creatorcontrib><title>Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>Allogeneic hematopoietic SCT is an effective treatment in accelerated (AP) or blast phase (BP) CML. Imatinib (IM) has transient but significant activity in advanced phases of CML, which may permit early allografting for responding patients. To identify prognostic factors in allograft recipients previously treated with IM, we analyzed 449 allogeneic hematopoietic SCTs performed from 1999 to 2004 in advanced-phase CML, using the data reported to the Center for International Blood and Marrow Transplant Research. CML patients in second chronic phase (CP2,
n
=184), AP (
n
=185) and BP (
n
=80) received HLA-identical sibling (27%), related (3%), or matched or mismatched unrelated donor (70%), peripheral blood (47%) or BM (53%) hematopoietic SCT after myeloablative (78%) or non-myeloablative (22%) conditioning. In all, 52% in CP2, 49% in AP and 46% in BP received IM before hematopoietic SCT. Disease-free survival was 35–40% for CP2, 26–27% for AP and 8–11% for BP. Cumulative incidence of acute and chronic GVHD and TRM were not affected by the stages of CML or pre-hematopoietic SCT IM exposure. Multivariate analyses showed that conventional prognostic indicators remain the strongest determinants of transplant outcomes. In conclusion, there are no new prognostic indicators of the outcomes of allogeneic hematopoietic SCT for advanced-phase CML in the IM era.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Benzamides</subject><subject>Biological and medical sciences</subject><subject>Blast</subject><subject>Blood</subject><subject>Bone marrow</subject><subject>Bone marrow transplantation</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Care and treatment</subject><subject>Cell Biology</subject><subject>Child</subject><subject>Chronic myeloid leukemia</subject><subject>Data processing</subject><subject>Disease-Free Survival</subject><subject>Donors</subject><subject>Female</subject><subject>Graft-versus-host reaction</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hematopoietic stem cells</subject><subject>Hemopoiesis</subject><subject>Histocompatibility antigen HLA</subject><subject>Humans</subject><subject>Imatinib</subject><subject>Imatinib Mesylate</subject><subject>Indicators</subject><subject>Inhibitor drugs</subject><subject>Internal Medicine</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multivariate analysis</subject><subject>original-article</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Peripheral blood</subject><subject>Piperazines - administration & dosage</subject><subject>Protein Kinase Inhibitors - administration & dosage</subject><subject>Public Health</subject><subject>Pyrimidines - administration & dosage</subject><subject>Retrospective Studies</subject><subject>Siblings</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Transplantation</subject><subject>Transplantation Conditioning</subject><subject>Transplantation, Homologous</subject><subject>Transplants & implants</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqN0s1rFDEYB-Agit1Wb55lQCwenDXfk3irix-FLYrU85DJZHZTMsk2yRz635txV9tKEZnDQPLkffPxA-AFgksEiXjXjXmJIUJLJOkjsEC04TUjnD0GC4i5qAnh8ggcp3QFIaIUsqfgCCMpOCd8Ady3GDY-pGx1NSidQ0zVEGIVpqzDaFJlfaWcCxvjTSE5Kp92Tvmssg3-F11drGeVt6ayYxn2tqtMVO8rVa3OP1xcfq-UV-4m2fQMPBmUS-b54X8Cfnz6eLn6Uq-_fj5fna1rzRnMdY-bfugpU33HDec9FoxDqZUWRjKieJkkndHUCIRIQwWHijRYYKEg5XpQ5AS82dfdxXA9mZTb0SZtXNm3CVNqEcRQUCak_A-KJJQEN7jQV3_RqzDFcrTUYk4xakQj2L9UqSU4Q6XrrdooZ1rrh1BuVs-t2zMsiaSSQFrU8gFVvt6MVgdvBlvG7y04vbNga5TL2xTcNL9Vug_f7qGOIaVohnYXy-PFm7LJdo5VW2LVzrFqS6wKf3k41NSNpv-Df-eogNcHoJJWbigx0TbdOiYlZGguVO9dKlN-Y-Ld23mg8U-4X9_E</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>Khoury, H J</creator><creator>Kukreja, M</creator><creator>Goldman, J M</creator><creator>Wang, T</creator><creator>Halter, J</creator><creator>Arora, M</creator><creator>Gupta, V</creator><creator>Rizzieri, D A</creator><creator>George, B</creator><creator>Keating, A</creator><creator>Gale, R P</creator><creator>Marks, D I</creator><creator>McCarthy, P L</creator><creator>Woolfrey, A</creator><creator>Szer, J</creator><creator>Giralt, S A</creator><creator>Maziarz, R T</creator><creator>Cortes, J</creator><creator>Horowitz, M M</creator><creator>Lee, S J</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20120601</creationdate><title>Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis</title><author>Khoury, H J ; Kukreja, M ; Goldman, J M ; Wang, T ; Halter, J ; Arora, M ; Gupta, V ; Rizzieri, D A ; George, B ; Keating, A ; Gale, R P ; Marks, D I ; McCarthy, P L ; Woolfrey, A ; Szer, J ; Giralt, S A ; Maziarz, R T ; Cortes, J ; Horowitz, M M ; Lee, S J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c650t-d27dfd45adb6e66d285609cac8e953a6dfd3bec4e811374860a372828a046cfa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Benzamides</topic><topic>Biological and medical sciences</topic><topic>Blast</topic><topic>Blood</topic><topic>Bone marrow</topic><topic>Bone marrow transplantation</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Care and treatment</topic><topic>Cell Biology</topic><topic>Child</topic><topic>Chronic myeloid leukemia</topic><topic>Data processing</topic><topic>Disease-Free Survival</topic><topic>Donors</topic><topic>Female</topic><topic>Graft-versus-host reaction</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hematopoietic stem cells</topic><topic>Hemopoiesis</topic><topic>Histocompatibility antigen HLA</topic><topic>Humans</topic><topic>Imatinib</topic><topic>Imatinib Mesylate</topic><topic>Indicators</topic><topic>Inhibitor drugs</topic><topic>Internal Medicine</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multivariate analysis</topic><topic>original-article</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Peripheral blood</topic><topic>Piperazines - administration & dosage</topic><topic>Protein Kinase Inhibitors - administration & dosage</topic><topic>Public Health</topic><topic>Pyrimidines - administration & dosage</topic><topic>Retrospective Studies</topic><topic>Siblings</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Transplantation</topic><topic>Transplantation Conditioning</topic><topic>Transplantation, Homologous</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khoury, H J</creatorcontrib><creatorcontrib>Kukreja, M</creatorcontrib><creatorcontrib>Goldman, J M</creatorcontrib><creatorcontrib>Wang, T</creatorcontrib><creatorcontrib>Halter, J</creatorcontrib><creatorcontrib>Arora, M</creatorcontrib><creatorcontrib>Gupta, V</creatorcontrib><creatorcontrib>Rizzieri, D A</creatorcontrib><creatorcontrib>George, B</creatorcontrib><creatorcontrib>Keating, A</creatorcontrib><creatorcontrib>Gale, R P</creatorcontrib><creatorcontrib>Marks, D I</creatorcontrib><creatorcontrib>McCarthy, P L</creatorcontrib><creatorcontrib>Woolfrey, A</creatorcontrib><creatorcontrib>Szer, J</creatorcontrib><creatorcontrib>Giralt, S A</creatorcontrib><creatorcontrib>Maziarz, R T</creatorcontrib><creatorcontrib>Cortes, J</creatorcontrib><creatorcontrib>Horowitz, M M</creatorcontrib><creatorcontrib>Lee, S J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khoury, H J</au><au>Kukreja, M</au><au>Goldman, J M</au><au>Wang, T</au><au>Halter, J</au><au>Arora, M</au><au>Gupta, V</au><au>Rizzieri, D A</au><au>George, B</au><au>Keating, A</au><au>Gale, R P</au><au>Marks, D I</au><au>McCarthy, P L</au><au>Woolfrey, A</au><au>Szer, J</au><au>Giralt, S A</au><au>Maziarz, R T</au><au>Cortes, J</au><au>Horowitz, M M</au><au>Lee, S J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>47</volume><issue>6</issue><spage>810</spage><epage>816</epage><pages>810-816</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><coden>BMTRE9</coden><abstract>Allogeneic hematopoietic SCT is an effective treatment in accelerated (AP) or blast phase (BP) CML. Imatinib (IM) has transient but significant activity in advanced phases of CML, which may permit early allografting for responding patients. To identify prognostic factors in allograft recipients previously treated with IM, we analyzed 449 allogeneic hematopoietic SCTs performed from 1999 to 2004 in advanced-phase CML, using the data reported to the Center for International Blood and Marrow Transplant Research. CML patients in second chronic phase (CP2,
n
=184), AP (
n
=185) and BP (
n
=80) received HLA-identical sibling (27%), related (3%), or matched or mismatched unrelated donor (70%), peripheral blood (47%) or BM (53%) hematopoietic SCT after myeloablative (78%) or non-myeloablative (22%) conditioning. In all, 52% in CP2, 49% in AP and 46% in BP received IM before hematopoietic SCT. Disease-free survival was 35–40% for CP2, 26–27% for AP and 8–11% for BP. Cumulative incidence of acute and chronic GVHD and TRM were not affected by the stages of CML or pre-hematopoietic SCT IM exposure. Multivariate analyses showed that conventional prognostic indicators remain the strongest determinants of transplant outcomes. In conclusion, there are no new prognostic indicators of the outcomes of allogeneic hematopoietic SCT for advanced-phase CML in the IM era.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>21986636</pmid><doi>10.1038/bmt.2011.194</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2012-06, Vol.47 (6), p.810-816 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1020845899 |
| source | MEDLINE; Nature Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SpringerLink Journals - AutoHoldings |
| subjects | Adolescent Adult Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Benzamides Biological and medical sciences Blast Blood Bone marrow Bone marrow transplantation Bone marrow, stem cells transplantation. Graft versus host reaction Care and treatment Cell Biology Child Chronic myeloid leukemia Data processing Disease-Free Survival Donors Female Graft-versus-host reaction Hematologic and hematopoietic diseases Hematology Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Hemopoiesis Histocompatibility antigen HLA Humans Imatinib Imatinib Mesylate Indicators Inhibitor drugs Internal Medicine Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical prognosis Medical sciences Medicine Medicine & Public Health Middle Aged Multivariate analysis original-article Patient outcomes Patients Peripheral blood Piperazines - administration & dosage Protein Kinase Inhibitors - administration & dosage Public Health Pyrimidines - administration & dosage Retrospective Studies Siblings Stem cell transplantation Stem Cells Survival Survival Rate Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation Transplantation Conditioning Transplantation, Homologous Transplants & implants |
| title | Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T05%3A44%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20factors%20for%20outcomes%20in%20allogeneic%20transplantation%20for%20CML%20in%20the%20imatinib%20era:%20a%20CIBMTR%20analysis&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Khoury,%20H%20J&rft.date=2012-06-01&rft.volume=47&rft.issue=6&rft.spage=810&rft.epage=816&rft.pages=810-816&rft.issn=0268-3369&rft.eissn=1476-5365&rft.coden=BMTRE9&rft_id=info:doi/10.1038/bmt.2011.194&rft_dat=%3Cgale_proqu%3EA293949304%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1018651993&rft_id=info:pmid/21986636&rft_galeid=A293949304&rfr_iscdi=true |